{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=34",
    "query": {
      "intervention": "Injectable Placebo",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 4209,
    "total_pages": 421,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=35&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=33&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T08:00:46.734Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05024344",
      "title": "ESP Block vs Control for Pain Control Following Percutaneous Nephrolithotomy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nephrolithotomy, Percutaneous"
      ],
      "interventions": [
        {
          "name": "Erector Spinae Plane Block",
          "type": "PROCEDURE"
        },
        {
          "name": "Ropivacaine 0.5% Injectable Solution",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University of Tennessee Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2021-08-09",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-10-20T08:00:46.734Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05024344"
    },
    {
      "nct_id": "NCT06326814",
      "title": "A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria"
      ],
      "interventions": [
        {
          "name": "Humanized anti-Factor Bb monoclonal antibody",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 54,
      "start_date": "2021-10-11",
      "completion_date": "2023-05-05",
      "has_results": false,
      "last_update_posted_date": "2024-03-22",
      "last_synced_at": "2026-10-20T08:00:46.734Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06326814"
    },
    {
      "nct_id": "NCT01950234",
      "title": "ACTH in Progressive Forms of MS",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Secondary Progressive Multiple Sclerosis",
        "Primary Progressive Multiple Sclerosis",
        "Progressive Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "ACTH",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2014-04-17",
      "completion_date": "2022-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-02-11",
      "last_synced_at": "2026-10-20T08:00:46.734Z",
      "location_count": 3,
      "location_summary": "Minneapolis, Minnesota • Fargo, North Dakota • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Fargo",
          "state": "North Dakota"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01950234"
    },
    {
      "nct_id": "NCT07500506",
      "title": "A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lyme Disease"
      ],
      "interventions": [
        {
          "name": "VLA15",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 1712,
      "start_date": "2026-04-08",
      "completion_date": "2026-12-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-20T08:00:46.734Z",
      "location_count": 19,
      "location_summary": "Bangor, Maine • Worcester, Massachusetts • Flemington, New Jersey + 13 more",
      "locations": [
        {
          "city": "Bangor",
          "state": "Maine"
        },
        {
          "city": "Bangor",
          "state": "Maine"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Flemington",
          "state": "New Jersey"
        },
        {
          "city": "Cortland",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07500506"
    },
    {
      "nct_id": "NCT06161116",
      "title": "Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "MK-6194",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 149,
      "start_date": "2023-12-27",
      "completion_date": "2025-07-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-20T08:00:46.734Z",
      "location_count": 19,
      "location_summary": "Covina, California • La Jolla, California • La Palma, California + 15 more",
      "locations": [
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Palma",
          "state": "California"
        },
        {
          "city": "Tujunga",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06161116"
    },
    {
      "nct_id": "NCT05514834",
      "title": "BCT-HA Kit for Dehydrated and Wrinkled Skin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Rhytides",
        "Wrinkle"
      ],
      "interventions": [
        {
          "name": "Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3)",
          "type": "DEVICE"
        },
        {
          "name": "PRP Only",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "30 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2022-06-10",
      "completion_date": "2024-02-29",
      "has_results": false,
      "last_update_posted_date": "2024-04-29",
      "last_synced_at": "2026-10-20T08:00:46.734Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05514834"
    },
    {
      "nct_id": "NCT01483599",
      "title": "A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "CNTO 1959 (5 mg)",
          "type": "DRUG"
        },
        {
          "name": "CNTO 1959 (15 mg)",
          "type": "DRUG"
        },
        {
          "name": "CNTO 1959 (50 mg)",
          "type": "DRUG"
        },
        {
          "name": "CNTO 1959 (100 mg)",
          "type": "DRUG"
        },
        {
          "name": "CNTO 1959 (200 mg)",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 293,
      "start_date": "2011-11-10",
      "completion_date": "2013-08-05",
      "has_results": true,
      "last_update_posted_date": "2017-08-02",
      "last_synced_at": "2026-10-20T08:00:46.734Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01483599"
    },
    {
      "nct_id": "NCT05784363",
      "title": "A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Enlarged Pores",
        "Sebum Production"
      ],
      "interventions": [
        {
          "name": "NT 201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merz North America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 31,
      "start_date": "2022-10-27",
      "completion_date": "2024-07-31",
      "has_results": false,
      "last_update_posted_date": "2024-08-23",
      "last_synced_at": "2026-10-20T08:00:46.734Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Coral Gables, Florida • Nashville, Tennessee",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05784363"
    },
    {
      "nct_id": "NCT05421598",
      "title": "Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Amlitelimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 437,
      "start_date": "2022-06-30",
      "completion_date": "2025-03-20",
      "has_results": true,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-10-20T08:00:46.734Z",
      "location_count": 21,
      "location_summary": "La Jolla, California • Los Angeles, California • San Jose, California + 18 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05421598"
    },
    {
      "nct_id": "NCT03416036",
      "title": "Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "TetraVax-DV-TV003 (TV003)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rDEN2Δ30-7169 (DENV-2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rDEN3Δ30 (DENV-3)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 64,
      "start_date": "2017-11-28",
      "completion_date": "2019-06-04",
      "has_results": false,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-10-20T08:00:46.734Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03416036"
    }
  ]
}